Large-scale production facility for proteins derived from genetically modified silkworms
First written in FY2016. 6 of 12 entries say "Restated". Latest entry: 2026-09-15.
No other company in this theme has enough history to compare yet.
- 2026-09-15ReframedBusiness Plan
「We will optimize management resources by reducing manufacturing costs and improving manufacturing-line utilization.」
The manufacturing structure for the TG silkworm service at 2 domestic sites was reorganized, with the Mikasa Research Institute to be closed and manufacturing consolidated at the Maebashi Research Institute. - FY2023AdvancedAnnual report
「With regard to research and development, although we have reached a point where we have a clear path to increasing the production yield of human-type collagen in cocoons, there was no significant progress in other research and development.」
The company stated that it had reached a point where it had a clear path to increasing the production yield of human-type collagen in cocoons with regard to large-scale production and productivity improvements. - FY2023-Q1RestatedAnnual report
「This business is focusing exclusively on basic research into developing useful proteins and improving the amount of such proteins produced in silkworm cocoons while controlling costs.」
The company continues to prioritize basic research into cost containment and improving the production yield of useful proteins over facility development with regard to large-scale production and the production system. - FY2022-Q2RestatedAnnual report
「We will focus on basic research aimed at increasing by approximately 10-fold the yield of antibodies and proteins obtained from a single cocoon.」
The company continues to shift its focus regarding large-scale production and the production system from facility development to basic research aimed at increasing yields by approximately 10-fold. - FY2022-Q1RestatedAnnual report
「However, in this business, research and development expenses are being incurred ahead of schedule because the company is intensively conducting basic research to increase recombinant protein yields by approximately 10-fold.」
The company is intensively pursuing basic research aimed at increasing recombinant protein yields by approximately 10-fold with regard to the production system and large-scale production. - FY2021ReframedAnnual report
「We will also conduct basic research aimed at reducing the production cost of recombinant proteins to approximately one-tenth, based on the data and experience accumulated to date, with the aim of commercializing pharmaceutical applications, and will continue researching and developing new drug seeds as a development-oriented venture company.」
The focus of large-scale production and the production system shifted from simply developing facilities to researching ways to reduce production costs to approximately one-tenth using accumulated data and identifying new drug seeds. - FY2021-Q3Research to increase production yield by at least 10-fold disclosedAnnual report
「Based on its accumulated data and experience, the company is conducting basic research to increase recombinant protein yields by at least 10-fold. It is also exploring ways to make effective use of the GMP manufacturing system developed through the manufacture of anti-HIV antibody drug substance, and will continue conducting research and development into new pharmaceutical seeds as a development-focused venture company.」
Regarding large-scale production and the production system, the company disclosed basic research aimed at increasing recombinant protein yields by at least 10-fold, as well as consideration of ways to use its existing GMP manufacturing system. - FY2020AdvancedAnnual report
「In the genetically modified silkworm business, the company renovated the Mikasa Research Institute to increase production capacity for human-type collagen I and III.」
With regard to large-scale production and the production system, the company proceeded with renovations to the research institute to increase production capacity for human-type collagen I and III. - FY2019RestatedAnnual report
「In the short term, we will promote the substitution of target proteins, including antibodies used in research reagents and in vitro diagnostic products, and their industrial use in applications such as cosmetic raw materials, with the aim of securing specific production orders. Over the medium to long term, we are actively advancing research and development of pharmaceutical raw materials, including the commercialization of raw materials for veterinary drugs and joint research on anti-HIV antibodies with CURED.」
The company continues to pursue plans to expand applications from research, diagnostic and cosmetic uses to raw materials for veterinary and human pharmaceuticals, as well as its policy of establishing production facilities and a production system. - FY2018-Q1RestatedAnnual report
「In joint research and development with Astellas Pharma Inc., we aim to increase the production yield of human-type fibrinogen produced from genetically modified silkworm cocoons and establish a stable method for large-scale rearing using large-scale rearing facilities.」
The company continues to pursue higher production yields for human-type fibrinogen and establish a stable large-scale rearing method using large-scale rearing facilities. - FY2017RestatedAnnual report
「We will continue investing in production facilities and related equipment for pharmaceutical raw materials, recruiting talented personnel and establishing a production system.」
The company has stated its policy of continuing to invest in production facilities and related equipment for pharmaceutical raw materials and establish a production system. - FY2016First statedAnnual report
「Establishment and equipment of a large-scale production facility for proteins produced by genetically modified silkworms」
The plan called for work to begin in the fiscal year ending March 2018 and completion in the fiscal year ending March 2019. The planned investment amount was listed as undetermined.